logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Daridorexant for Insomnia

< Back

Daridorexant for Insomnia

Drugs

Neurology and Neurosurgery

February 2020


Daridorexant is a medicinal product in clinical development for the treatment of adults with insomnia. Insomnia means regularly having problems sleeping, which results in impaired daytime functioning. Insomnia can be categorised according to its duration, into short-term insomnia (lasting less than 4 weeks) and long-term (or persistent) insomnia (lasting 4 weeks or longer).
Daridorexant is a drug which reduces excessive alertness, in contrast to treatments of insomnia that sedates the central nervous system. As a result, daridorexant offers the potential to induce and maintain sleep, through all stages of sleep. Daridorexant is quickly absorbed in the body, resulting in a fast onset of action. Daridorexant is given orally as tablets. If licensed, daridorexant could represent an additional treatment option for patients with insomnia.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts